Emboline Secures $20 Million in Growth Funding

Emboline, a medical technology firm based in Santa Cruz, California, has successfully raised $20 million in a growth funding round. This financing was led by Trinity Capital, an international alternative asset manager. Emboline specializes in developing the Emboliner®, a total-body embolic protection system designed to capture debris during transcatheter procedures, helping reduce stroke and ischemic complications.

Company Leadership and Vision

The company is helmed by Scott Russell, who serves as President and CEO. Russell emphasized the importance of this funding round, noting, "We are excited to partner with Trinity Capital at a pivotal moment for Emboline. With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year."

Strategic Use of Funds

The newly acquired capital will be directed towards several key initiatives:

  • Commercial Launch: Emboline is gearing up for the commercial introduction of its Emboliner system in the U.S. and European markets. Preparations are underway, with plans to launch later this year.
  • Technology Development: The funds will also support the ongoing development of Emboline's embolic protection technology platform, which aims to further reduce embolic risk during structural heart procedures.

Recent Developments and Future Plans

Emboline recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial. This prospective randomized study evaluates the effectiveness of the Emboliner system. Results from the trial are scheduled to be presented at the American College of Cardiology Annual Scientific Session in New Orleans on March 29, 2026.

Investor Insights

Trinity Capital expressed its support for Emboline at this crucial juncture. Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, commented, "Emboline's embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications. We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide."

This funding milestone positions Emboline to make significant strides in the commercialization and further development of its innovative medical technology solutions.